Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: expert statement
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: expert statement
- Executive summary:
Direct toxicokinetic data are not available on the test item. Certain physico-chemical properties suggest potential absorption at a limited level. The two repeated dose oral administration studies resulted in some microscopic changes in liver and kidney in rats treated with 50 or 120 mg/kg bw/day. Recovery was evident after treatment was stopped. These biological effects provide qualitative evidence that in rats at least, intestinal absorption, and subsequent tissue distribution, cellular uptake and biological effects of the test item or its metabolites take place.
Reference
Description of key information
There is no specific requirement to generate TK information in REACH. (R.7.12.1). There are no adequate studies that specifically address toxicokinetics (i.e. absorption, metabolism, distribution and elimination). However, physical-chemical properties were used to estimate absorption via oral, dermal and inhalation exposures. Animal data from repeated dose studies provide some evidence of absorption and distribution based on certain biological effects observed. The 90-day repeated dose oral administration study in rats resulted in microscopic liver changes (bile duct hyperplasia associated with inflammatory cell infiltration and pigment deposits in bile ducts) and some non-adverse kidney changes (hyaline droplets) in males treated with 120 mg/kg bw/day and adaptive liver changes (hypertrophy) in females treated with 120 mg/kg bw/day. Recovery was evident after treatment was stopped. Liver effects were also seen in another rat study of shorter duration (OECD 422). These biological effects provide qualitative evidence that in rats atleast, intestinal absorption, and subsequent tissue distribution, cellular uptake and bilogical effects take place.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 25
- Absorption rate - inhalation (%):
- 100
Additional information
Toxicokinetics Summary
There is no specific requirement to generate toxicokinetic information in REACH. (R.7.12.1).
A. There is no specific requirement to generate toxicokinetic information in REACH. (R.7.12.1). There are no adequate studies that completely address toxicokinetics (i.e. absorption, metabolism, distribution and elimination) of the test substance, 1,2,4,5,7,8-Hexoxonane, 3,6,9-trimethyl-, 3,6,9-tris(Ethyl and Propyl) derivatives,CAS# 1613243 -54 -1. Available physicochemical properties are as follows:
MW |
WS (Water Solubility) |
Log P |
Vapor Pressure |
systemic toxicity |
|
Average: 273 (range: 264-306) |
19.6 mg/L @ 20 oC |
6 |
66 Pa @ 25 oC |
Yes, oral (OECD 408 and 422) |
Oral Absorption: There is no quantitative information on the oral absorption of this peroxide. While the water solubility would not favor absorption, a repeat dose study (OECD 422) indicates systemic effects (microscopic changes in liver and heart) providing an evidence that some of the administered test item was absorbed when administered orally.
Dermal Absorption: Per ECHA Guidance on information requirements and chemical safety assessment Chapter R.7c: Endpoint specific guidance for dermal absorption:
MW: <100 favors absorption; > 500 does not
WS: 1-100 mg/L absorption is low to moderate
Log P: 1-4 favors absorption, > 4 penetration is limited by rate of transfer between stratum corneum and epidermis
VP: vapors with < 100 Pa are likely to be well absorbed and the amount absorbed dermally may be more than 10% of the amount that would be absorbed by inhalation.
Based on the above guidance and physical-chemical properties, dermal absorption of the test substance is estimated to be ~25% of oral absorption.
Inhalation Absorption: Per ECHA Guidance on information requirements and chemical safety assessment Chapter R.7c: Endpoint specific guidance for inhalation absorption:
VP: substances with VPs < 0.5 KPA have low volatility
Log P: > 4 favors micellular solubilization if poor WS (1 mg/L or less)
WS: low WS enhance penetration to lower respiratory tract.
Animal data from repeated dose studies provide some evidence of absorption and distribution based on certain biological effects observed. The 90-day repeated dose oral administration study in rats resulted in microscopic liver changes (bile duct hyperplasia associated with inflammatory cell infiltration and pigment deposits in bile ducts) and some non-adverse kidney changes (hyaline droplets) in males treated with 120 mg/kg bw/day and adaptive liver changes (hypertrophy) in females treated with 120 mg/kg bw/day. Recovery was evident after treatment was stopped. Liver effects were also seen in another rat study of shorter duration (OECD 422). These biological effects provide qualitative evidence that in rats atleast, intestinal absorption, and subsequent tissue distribution, cellular uptake and bilogical effects take place.
B. Supporting evidence: Available information on 1,2,4,5,7,8 -Hexoxonane, 3,6,9 -triethyl-3,6,9 -trimethyl-(CAS# 24748 -23 -0), a cyclic peroxy ketone, which is a major constituentof the test substance (CAS# 1613243 -54 -1) is provided below.:
MW |
Water Solubility |
Log P |
Vapor Pressure |
Surface Tension |
Systemic toxicity |
264 |
13.1 mg/L (slightly soluble) |
4.84 |
4.1 Pa (0.0041 KPa) |
Log10 Koc 3.16 |
Yes, oral 90-day |
No studies are available on the toxicokinetics, metabolism and distribution of this substance. The pure peroxide is not commercially available.
Oral Absorption:There is no information on the oral absorption of this peroxide. While the water solubility would not favor absorption, repeat dose studies indicate systemic effects (liver, kidney and blood).
In a hydrolysis study, OECD 111, under the physiologically relevant conditions of pH 1.2, 37.0 ± 0.5 °C, the mean half-life of the test item was determined to be 0.23 hours (14 minutes), with a rate constant of 8.41 x 10-4s-1.
Dermal Absorption:Per ECHA Guidance on information requirements and chemical safety assessment Chapter R.7c: Endpoint specific guidance for dermal absorption:
MW: <100 favors absorption; > 500 does not
WS: 1-100 mg/L absorption is low to moderate
Log P: > 4 penetration is limited by rate of transfer between stratum corneum and epidermis
VP: vapors with < 100 Pa are likely to be well absorbed and the amount absorbeddermally may be morethan 10% of the amount that would be absorbed by inhalation.
Inhalation Absorption :Per ECHA Guidance on information requirements and chemical safety assessment Chapter R.7c: Endpoint specific guidance for inhalation absorption:
VP: substances with VPs < 0.5 KPA have low volatility
Log P: > 4 favors micellular solubilization if poor WS (1 mg/L or less)
WS: low WS enhance penetration to lower respiratory tract.
Based on the above guidance and physical-chemical properties, dermal absorption of the registered substance is estimated to be low compared to oral absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.